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1. Introduction 
In patients with acute thoracic pain and non-conclusive acute myocardial infarction 
electrocardiogram (non-STEMI), the biochemical diagnosis is an essential tool for its correct 
treatment. The study of the chosen biomarker for cardiac injury has raised interest during 
decades. The appearance of immunoassays to assess cardiac troponin I or T has reached 
great improvements in the diagnosis, evolution and prognosis of the Acute Coronary 
Syndrome (ACS), as well as in risk stratification of these patients and in patients with 
chronic cardiac diseases as heart failure or cardiomyopathies. Regarding the analytical 
sensitivity of the methods that evaluate cardiac troponin I or T these improvements have 
made possible to measure accurately very tiny seric concentrations of the protein (high 
sensitivity troponin) (hs-Tn). This fact, being positive in principle sometimes induces to 
reconsider if tiny seric concentrations of isolated troponin I or T are not due to acute 
myocardial infarction but to a less severe source which affects the myocardiocite, this will 
oblige us to assess the clinical presentation in depth.  
2. Diagnostic criteria of acute coronary syndrome – Biochemical markers – 
History background and evolution 
Thoracic pain is one of the most frequent reasons for attending the emergengy room at 
hospitals. About 10% of these patients will be diagnosed Acute Myocardial Infarction. The 
clinical syntoms and the electrocardiogram can not always differentiate between a patient 
suffering from acute myocardial infarction or an angina. Electrocardiogram is only 
diagnostic in 40% of the patients. That is why in processes of acute coronary ischemia 
different from infarction with rising of segment ST, (infarction no Q or without rising of ST, 
unstable angina), the use of biochemical markers can be the only criteria to identify the 
existence of myocardial necrosis, being necessary for infarction diagnosis, treatment, 
evolution and prognosis. 
The biochemical diagnosis of acute coronary syndrome has had remarkable changes over 
the last few years. During years the enzymatic profile (creatine kinase, activity of the 
isoenzime CKMB, aspartate aminotransferase and lactate deshidrogenase) has been the 
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biochemical method chosen for the diagnosis of acute coronary ischemia. The criteria of the 
WHO (WHO 1979 ) was followed until 1999, being the catalytic activity of creatine kinase 
MB isoenzyme (CKMB) the marker chosen. In fact, according to the WHO to reach the 
diagnosis of acute myocardial infarction (AMI) two of the following three criterias must be 
fulfilled: precordial pain with evolution longer than 30 minutes, specific electrocardiograph 
changes and elevation of catalityc activity of creatine kinase (CK) and its isoenzime MB 
(CKMB). 
However, during the 1990s more sensitive and specific cardiac markers are marketed and 
beginning to be used in order to detect the disease, such as the protein concentration of 
isoenzime MB (CKMBmass) or Troponin. 
In September 2000 the criteria which defines acute myocardial infarction (AMI) was 
reviewed and a consensus document was published (European Society of Cardiology/ American 
College of Cardiology Committe 2000) between The Joint European Society of Cardiology and 
The American College of Cardiology where they give great importance to the alterations of 
cardiac markers: Troponin or CKMBmass (no activity) for the diagnosis of the disease, 
together with symptoms of ischemia or alterations in the electrocardiogram (ECG). In fact, 
the main criteria to establish the diagnosis of acute myocardial infarction is to verify the 
gradual release of troponin or CKMBmass, (typical curve of fast rising-descent), together 
with at least one of the following alterations: a) ischemic syntoms; b) development of 
pathological Q waves in ECG; c) indicative changes of ischemia (variations of the segment 
ST,T)  
2.1 Cardiact troponin: Biochemical bases  
Troponin is one of the myofibrilar proteins of the skeletal muscle and its function is to 
regulate muscular contraction in relation with calcium ion (Figure 1). The thick filament of 
the muscle is formed by myosin and the thin filament by actin, troponin and tropomyiosin. 
Only actin and myosin are contractile proteins; troponin and tropomyosin are regulatory. 
Troponin is composed by three peptides called troponin T, troponin I and troponin C. 
Troponin T is regulatory of tropomyosin; troponin I (inhibitory), inhibits the union actin-
myosin; troponin C is the receptor of calcium so when linking calcium disappears the 
inhibition of troponin I on tropomyosin forming the shuttles actin-myosin and activating the 
contraction.  
The theory currently accepted for the mechanism of muscular contraction involves the ATP-
asic activity (two molecules of ADP and inorganic phosphorus) present in the heads of 
myosin (figure 1). In repose myosin does not contact actin as the sarcplasm does not have 
enough calcium to produce the contraction, and calcium regulates the ATP-asic activity. 
During the contraction when receiving the nervous signal calcium is released to the 
sarcoplasm, this calcium joins immediately to the centers of union of calcium to troponin, 
inducing a structure change which allows the heads of actin and myosin to link forming an 
angle of about 90ºC. The release of the phosphorus molecule of the complex actin-myosin-
ADP involves a structure change which makes actin slide (power strike) and adopt a 45ºC 
angle on myosin. This movement produces at the same time a release of ADP. For each actin 
myosin union provoked by the union of two calcium molecules to troponin C, at least two 
ATP molecules are needed and to carry two calcium molecules from the cytosol to reticule 
an ATP molecule is required (Galán A. 2000).  
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Fig. 1. Scheme of the process of muscular contraction and involvement of myofibrilar and 
contractile proteins of the skeletal muscle (Galán A. 2000).  
The different kinds of muscles of the organism present different characteristics of 
contraction, this is due to the structural differences genetically determined in some 
myofibrilar proteins. Three isoforms have been described for troponin I and T which present 
structural differences codified by genes located in three different crhomosomes. So for 
troponin I (figure 2) there are two isoforms of the skeletal muscle one of slow contraction 
and another one fast and a specific shape of the cardiac muscle. The cardiac isoform has 31 
suplementary aminoacids at the N-terminal end of the polypeptide chain and besides it 
differs from skeletal isoforms as it shows in the tracts of the primary sequences of the 
protein, a heterogeneity of 69% for the central tract (residues 30 to 110) and 44% for the 
terminal tract (110-215) which seems to be more stable because of the protection carried out 
by the subunit C terminal. Troponin T also shows three isoforms codified by genes located 
in three different chromosomes, one of them is specific for myocardium. The myocardial 
isoform has an elevated polymorphism provoking isoforms which express in injured 
myocardial tissue, adult and fetal. Troponin C, however, is identical in both kinds of muscle. 
(Galán A. 2004).  
This fact confers troponin the qualification of cardiac marker of maximum cardiospecificity 
unlike creatine kinase, creatine kinase MB and myoglobine which co-express in the skeletal 
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muscle and in the myocardium. Some specific anti-bodies have been patented in opposition 
to troponin T and cardiac Troponin I so that they can be recognised by specific 
immunoassays. Troponin forms (I and T) of skeletal and cardiac muscle: a) Are codified by 
different genes; b) Have structures which are clearly differentiated; c) Are recognised by 
specific immunoassays. 
That is why the assessment of troponin T or troponin I favours the specific recognition of 
myocardial damage even in the presence of concomitant skeletal muscle damage. Therefore 
only troponin molecules fulfil the cardiospecificity criteria. This cardiospecificity guarantees 
that the detection of a cardiac troponin molecule in plasma is indicative of myocardial 
injury. 
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Fig. 2. Isoforms of Troponin I: In the figure we can see two isoforms of skeletal muscle, one 
of slow contraction and another one fast and a specific form of cardiac muscle. The cardiac 
isoform has 31 suplementary aminoacids at the end N-terminal of the polypeptide chain, 
besides it differs from skeletal isoforms as it shows in the tracts of the primary sequence of 
the protein a heterogeneity of 69% for the central tract (residues 30 to 110) and 44% for the 
terminal tract (110-215) which seems to be more stable because of the protection carried out 
by the subunit C terminal (Galän A 2004).  
We confirmed the absence of crossed reactions (Galán A. 2002) for an Immunoassay 
Troponin I (cat. nº RF421 Dade Behring) using the Dimension RxL automatic analyzer (Dade 
Behring, Newark, Delaware, USA). The cardiospecificity of troponin I was verified using 
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myocardial and skeletal muscle (quadriceps, biceps) tissue. Troponin I was measured in 
myofibrillar and cytosolic fraction. The absence of troponin I in skeletal muscle was 
corroborated: the concentration of troponin I in biceps and quadriceps was not detected (< 
1% of the values obtained in myocardial tissue). The troponin I concentration in the 
myofibrillar fraction of cardiac tissue was 7.2 mg/g protein and only 4% of total troponin 
content was found in the soluble fraction (figure 3). 
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Fig. 3. Tissue specificity for the troponin I method. The figure shows the lack of 
crossreactivity of troponin I with skeletal muscle. No troponin I concentrations in the crude 
extract of biceps and quadriceps were detected. The troponin I concentration in the 
myofibrillar fraction of cardiac tissue was 7.2 mg/g protein and in the cytosolic fraction 0.3 
mg/g protein. (Galán A. 2002) 
This fact helps to understand the double diagnostic window of troponin: The small fraction 
dissolved in cytoplasma of the cardiomyocites, which has relative precociousness (>6 hours) 
in the detection of cellular injuries (similar to other cytoplasmatic proteins) and the majority 
fraction which is the one linked to tropomyosin complex in structure and only appears in 
plasma after cellular irreversible damage and after 40 hours from occurring and remains 
elevated till 10-15 days after the injury, being then used as late marker of myocardial 
necrosis (figure 4)  
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Fig. 4. Plasmatic levels of cardiac markers after ischemic process: Double diagnostic window 
of Troponin 
2.2 Comparative characteristics of troponin with other cardiac markers 
Myoglobine and CKMB are located in the cellular cytoplasma which favours a fast exit of the 
molecule out of the cell and therefore an early appearance in systemic circulation. Troponin 
has a small fraction in cellular cytoplasma but most of it is found in deep tissue, as part of 
tropomyosin complexes. On the other hand either myoglobin or CK-MB co-express in skeletal 
muscle so they do not have the cardiospecificity which troponin shows (Table 1). 
 
CARDIAC 
BIOMARKER  
  
TISSUE
 LOCATION 
 
MOLECULA R
WEIGHT 
(dalton) 
 
CELLULAR
 LOCATION 
 
 
 
MIOGLOBIN Heart  muscle 
Skeletal muscle     
17.800 Cytosol 
 
 
CK-MB Heart  muscle 
Skeletal muscle     
80.000  Cytosol 
 
 
Cardiac 
TROPONIN I 
 
   
Heart  muscle 
 
23.500 3%  Cytosol 
97% Tropomyosin 
Complex 
 
Cardiac 
TROPONIN T 
 
Heart  muscle 
 
33.000 6 %  Cytosol 
94% Tropomyosin 
Complex 
 
 
Table 1. Molecular Weight and cellular and tissue location. 
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Myoglobin and CK isoforms are the earliest markers and with the fastest elimination. CKMB 
is cytosolic but it has higher PM than Myoglobin so it takes it longer to appear and clear the 
plasma. Troponin, due to its double location has a wide diagnostic window (from 6 hours to 
10-12 days) (Table 2) 
 
CARDIAC 
MAR KER 
Home 
elevation 
after AMI  
(houres) 
peak elevation 
 (houres) 
Return 
Nor mal 
Value 
(houres) 
 
 
 
 
 
CKM B 
ISOFORM S 
 
2 -4 6 -8 18-2 4 houres
MIOGLOBIN 2 -3 6- 9 18-2 4 houres
CK-M B 4 -6 10- 18 1-2  days  
T ROPONIN I >6 10- 24 5 -10 days  
T ROPONIN 
T 
>6 10- 24 5 -12 days  
 
 
 
Table 2. Cardiac marker Kinetics. 
Cardiac troponin has a small fraction (6% for T and 3% for I) dissolved in cytoplasma of the 
cardiomyocites. This confers the early detection of cellular damage similar to that of other 
cytoplasmatic proteins, even better than the isoenzime MB of creatine kinase because its 
molar mass is lower (33.000 g/mol para la T y 23.500 g/mol para la I). Nevertheless, the 
majority fraction, approximately 90%, is linked in structure to the tropomyosin complex and 
only appears in plasma after irreversible cellular damage and 40 hours after occurring. 
Besides, as it remains in plasma for a long time it can also be used as late marker of 
myocardial necrosis. 
Because of all of this, the excellent cardiospecificity and sensitivity of troponin for the 
detection of myocardial necrosis, together with its wide diagnostic window (from 6-12h to 5-
10 days for troponin I and from 6-12 hours to 5-15 days for troponin T) have revolutionised 
in the latest years the approach of patients with acute coronary syndrome as a lot of studies 
have demonstrated its usefulness in the diagnosis of myocardial necrosis as well as in the 
prognostic stratification of these patients in the first hours of evolution. 
2.3 Problem of the methods to assess troponin. Solutions taken. Guidelines for 
clinical practice 1999 and 2001 
In the beginning of working with troponin, either physician or biochemists wondered : Is 
troponin so useful?, Which troponin method is the right one? (Troponin T or Troponin I), 
What cut-off must we choose?, What marker or markers must be selected?, What intervals 
must be used? 
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At present there are black spots in the analytical management of the methods which assess 
troponin as the election for cut-off or the lack of standardization of the different methods 
available in the market (Wu Alan HB 2001), (Apple FS, 2001) and the low analytical 
sensitivity of the methods among others. These factors may cause confusion in the election 
of the method as well as in the clinical interpretation of the results (Table 3). 
 
• The choice of cutoff
• Lack of Tn I method’s estandarization
• Low sensitivity of methods
These factors may cause confusion
in the interpretation of results
 
Table 3. Technical problems in management troponin methods. 
To try to help and encourage us to use troponin, in 1999 appeared the first Guidelines for 
Clinical Practice in the use of troponin published by the National Academy of Clinical 
Biochemistry (NACB) to establish analytical and clinical recommendations (Wu AHB 1999) 
and in 2001 the standardization committee of cardiac markers of the International 
Federation of Clinical Chemistry (IFCC) opted for troponin as election marker for 
myocardial necrosis and establishes recommendations of analytical and pre-analitical 
quality for the assays of Tn, ( Panteghini M 2001), encouraging the clinical laboratories to 
use it and inducing the manufacturers to improve the analytical quality of the methods of 
assessment of the protein. 
An example of the problems was the discrepancy arisen when establishing the cut-offs 
according to the criteria of the different scientific societies: The NACB suggests using the 
ROC curves of sensitivity and diagnostic specificity choosing two cut-offs (AMI and 
myocardial damage) or just one cut-off of myocarid damage. Another alternative is to 
establish Reference Values in normal population and apply 95th percentile as the National 
Academy of Clinical Biochemistry (NACB) suggests or 99th percentile as the American 
College of Cardiology suggests (ACC). 
Another important problem is the election of the method (table 4). There is only one 
method in the market to measure TnT and innumerable methods to measure Tn I. The 
results of the different methods which measure Tn I are not overlapping, which generates 
doubts about its election. This variability of results does not occur with TnT methods as 
there is only one TnT immunoanalisis marketed. However, TnT values are not 
overlapping either with the methods which measure Troponin I. The molecular structure 
of TnI favours its heterogeneity. In serum there is variability of forms of TnI by oxidation, 
phosphorilation or protelisis affecting the interaction with anti-bodies in the assays. 
Besides, the heterogeneity in plasma of the different forms of troponin is another reason 
that makes it difficult to select the method. In blood we can find tissular forms of troponin 
making binary or ternary troponin complexes and free cytosolic forms (Figure 5). 
Therefore the anti-bodies used in the immunoassays of TnI detect different epitopes in 
free and complexed forms. 
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• Heterogeneity in plasma of the different forms of troponin
– Tissular forms:
binary troponin complexes  (I +C)
ternary troponin complexes (T+I+C)
– Free cytosolic forms  (I and T)
• There is any reference material to standardize marketed troponin
methods
• The antibodies used in the immunoassays of TnI detect different 
epitopes in free and complexed forms.  
Table 4. Reasons difficult the election of the method. 
 
 
Fig. 5. Scheme of the release in blood of cardiac sub-units of troponin after acute myocardial 
infarction (according to Wu y cols.) (Galan2004). 
So the main problem regarding the methods that assess troponin is the lack of 
standardization (Figure 6). As a consequence of that there is no transferring of the results 
among the different commercial methods which assess this protein, what creates confusion 
due to the analytical and clinical variability of the results. This makes it difficult to choose 
the best method.  
The absence of a material of reference which standardizes the methods means that the 
results obtained can not be transferred. The methods will have a different cut-off, variations 
in the limit of the cut-off, as well as imprecisions. On the other hand at low levels close to 
the reference values the coefficients of variation are elevated. 
The most suitable solution in the long run, as it is a difficult matter, to solve this problem is 
to obtain international reference material, a topic in which scientific societies as IFCC and 
AACC (American Society of Clinical Chemistry) among others have been working on since 
2001. This would standardize the methods and the transferring of the results would be 
achieved. What would not be unified is the variation of anti-bodies every manufacturer 
uses. The problem is not completely solved as the reference material obtained, more 
suitable, was elaborated by a sub-committee of standardization of the AACC in 
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collaboration with the National Institute of Standards and Technology (NIST) and certified 
in 2006 as standard reference material SRM # 2921. This reference material achieves 
commutability only with 50% of the commercial methods which assess troponin. In any 
case, the standardization of the measurement methods of troponin is not finished yet, which 
involves wide analytical variations noticed among the different immunoassays marketed 
and appoved by the FDA. (Wu Alan HB 2001).  
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Fig. 6. Analitical problems of the methods which assess troponin: Absence of 
standardization of the methods. 
The immediate solution the user must opt is: Choose the immunoassay which best adapts 
the infrastructure of the centre (central laboratory, emergency laboratory, or at the patients’ 
side) (bear in mind the analytic system available) and demand the manufacturers the 
technical documentation about what their method measures. The black spots must be 
evaluated by the user itself. In case that the imprecision of the chosen method does not fulfil 
the NABC indications at the point of diagnostic decision, the improvement of the method 
must be claimed to the manufacturer. 
Another important shortage of the initial methods of quantification of troponin is its relative 
sensitivity (figure 7)  
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Relative sensitivity
Figure 7. PROBLEM OF INITIAL TROPONONIN METHODS 
uncertainty in the diagnostic sensitivity 
of necrosis detection.
High coefficients of variation at levels
near of the lower limit of the reference values
 
Fig. 7. Problem of initial troponin methods. 
In general the methods of assessment of troponin showed elevated values in the limits of 
detection, limits of quantification far from the reference values, high imprecisions in the 
limits of quantification, cut-off and reference values, which provokes uncertainty in the 
diagnostic sensitivity of necrosis detection.  
That is why the goals of analytic quality of the different scientific societies have been: 
Recommend the use of methods to assess troponin with the maximum analytical sensitivity 
to increase the diagnostic sensitivity of the test in myocardial necrosis as well as avoiding 
the problems arising because of the lack of standardization of methods. 
2.4 Guidelines of clinical practice 2007 
In 2007, The Joint ESC/ACF/AHA/ WHF Task Force 2007 (Thygesen 2007) published 
the last Guidelines of Clinical Practice on the recommendations of the biochemical 
diagnosis of the detection of ACS and re-define the criteria for Myocardial Infarction 
establishing a universal definition of AMI. The recommendation (class I) state: In 
presence of clinical evidence (symptoms or alterations in ECG), concentrations of seric 
troponin higher than 99th percentile of the interval of reference of the method (with 
optimal analytic precision CV<10%), are indicative of myocardial necrosis. If troponin is 
not available the measurement of CKMB-mass is another acceptable alternative. The 
extraction of blood must be carried out at patient’s admission and 6 – 9 hours after 
admission.  
www.intechopen.com
  
Acute Coronary Syndromes 
 
56
These Guidelines are in accordance with the latest analytic recommendations for the use 
of troponin published in 2007 by the National Academy of Clinical Biochemistry (NACB) 
and the Committee of standardization of Cardiac Markers of the IFCC (NACB 2007) 
which state that: To establish reference values 99th percentile must be applied on a 
population of at least 120 subjects exempt from myocardial damage. It is required that the 
imprecision of the method in the 99th percentile chosen is lower or equal to a coefficient of 
variation of 10%.  
3. Methods of new generation: High-sensitivity assays 
The recommendations of these Clinical Guidelines have induced the manufacturers to 
market methods which assess the protein with higher reliability. This has provoked the 
appearance in the market of a new generation of immunoassays which assess troponin.  
 
Figure 8.  New Generation of Troponin methods
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Fig. 8. New generation of troponin methods. 
(Figure 8) They are methods with elevated analitic sensitivity and their goal is to detect the 
99th percentile of the limit of the detection, quantification limit and normal population with 
high analitic precision being able to fulfil the recommendations of the scientific societies. 
The goal of these methods is to be able to know with reliability the early diagnosis of the 
necrosis and the stratification of myocardial risk. There is a recent publication of Jaffé 2010 
which collects the characteristics of analytic sensitivity of all the methods of troponin in the 
market (table 5, ref Jaffé 2010).  
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Company-Instrument-
Assay (generation) 
Detection 
limit 
(ug/L) 
cTn at 99th 
percentile 
(ug/L) 
CV at 99th 
percentile (%) 
cTn at 
10% CV 
(ug/L) 
Abbott AxSYM ADV (2nd) 0.02 0.04 15.0 0.16 
Abbott ARCHITECT <0.01 0.028 15.0 0.032 
Abbott i-STAT 0.02 0.08# 16.5 0.10 
Beckman Coulter Access 
Accu (2nd) 
0.01 0.04 14.0 0.06 
bioMerieux Vidas Ultra 
(2nd) 
0.01 0.01 27.7 0.11 
Innotrac Aio! (2nd) 0.006 0.015 
14.0
(at 19 ng/L) 
0.036 
Inverness Biosite Triage 0.05 <0.05 NA NA 
Inverness Biosite Triage (r) 0.01 0.056 17.0 NA 
Mitsubishi Chemical 
PATHFAST 
0.008 0.029 5.0 0014 
Ortho Vitros ECi ES 0.012 0.034 10.0 0.034 
Radiometer AQT90 0.0095 0.023 17.7 0.039 
Response Biomedical 
RAMP 
0.03 <0.1 18.5 0.21 
Roche E170  0.01 <0.01 18.0 0.03 
Roche Elecsys 2010 0.01 <0.01 18.0 0.030 
Roche Cardiac Reader <0.05 <0.05 NA NA 
Siemens Centaur Ultra 0.006 0.04 10.0 0.03 
Siemens Dimension RxL 0.04 0.07 20.0 0.14 
Siemens Immulite 2500 
STAT 
0.1 0.2 NA 0.42 
Siemens Immulite 
1000Turbo 
0.15 NA NA 0.64 
Siemens Stratus CS 0.03 0.07 10.0 0.06 
Siemens VISTA 0.015 0.045 10.0 0.04 
Tosoh AIA II  0.06 <0.06 8.5 0.09 
NA= not assayed 99th = 99th percentile; 10% CV = Concentration measured with a 10% of total 
imprecision measured as coefficient of variation (CV); (r) = revised assay submitted to FDA per 
Inverness. Table can be consulted at http://www.ifcc.org/PDF/ScientificActivities/Committees/C-
SMCD/cTn_Assay_Table_v091209.pdf. Version updated September 12, 2009 
Table 5. Analytical characteristics of the current cardiac troponin I and T assays. (source) 
Troponinas ultrasensibles en el dolor torácico y los síndromes coronarios agudos. ¿un paso 
hacia delante? A.S. Jaffé y J.Ordoñez-Llanos. Rev Esp Cardiol, 2010; 63(7)763-68  
There are only 4 of them which fulfil the recommendations of the Guidelines for Clinical 
Practice into effect at present (Thygesen 2007) , (NCB 2007) (CV< 10% in 99th percentile). 
However, at present there is no recommendation in any Clinical Guideline which classifies 
high sensitivity methods. Apple et al 1999 have suggested a classification to differentiate such 
methods. They use two criterias a) coefficient of variation in 99th percentile and b) percentege 
of values detected in reference population. For a method to be ultra-sensitive must have 
CV<10% in 99th percentile and detect troponin in less than 50% of the reference population. 
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Table 6 (from Jaffé 2010) holds the classification of the methods available in the market to 
assess troponin according to the criteria of Apple 1999. None of the 16 methods mentioned in 
the table fulfil the two conditions Apple demands in their criteria of high sensitivity method  
 
 
99th 
percentile 
(in ng/L) 
Imprecision at 
99th percentile 
(%) 
Classification 
according 
imprecision 
% of detectable 
values in 
reference 
subjects 
Current available assays (generation) 
Abbott AxSYM ADV (2nd) 40 15.0 Clinically <50% 
Abbott ARCHITECT 28 15.0 Clinically <50% 
Abbott i-STAT 80 16.5 Clinically <50% 
Beckman Coulter Access 
Accu (2nd) 
40 14.0 Clinically 50-75% 
bioMerieux Vidas Ultra (2nd) 10 27.7 Not acceptable <50% 
Innotrac Aio! (2nd) 15 14.0 (at 19 ng/L) Clinically <50% 
Inverness Biosite Triage <50 NA NA <50% 
Inverness Biosite Triage (r) 56 17.0 Clinically Unknown 
Mitsubishi Chemical 
PATHFAST 
29 5.0 Guideline <50% 
Ortho Vitros ECi ES  34 10.0 Guideline <50% 
Radiometer AQT90 23 17.7 Clinically <50% 
Response Biomedical RAMP <100 18.5 Clinically <50% 
Roche E170  <10 18.0 Clinically <50% 
Roche Elecsys 2010  <10 18.0 Clinically <50% 
Roche Cardiac Reader  <50 NA NA <50% 
Siemens Centaur Ultra  40 10.0 Guideline <50% 
Siemens Dimension RxL  70 20.0 Clinically <50% 
Siemens Immulite 2500 
STAT 
200 NA NA <50% 
Siemens Immulite 1000 
Turbo 
NA NA NA <50% 
Siemens Stratus CS  70 10.0 Guideline <50% 
Siemens VISTA  45 10.0 Guideline <50% 
Tosoh AIA II  <60 8.5 Guideline <50% 
Research high-sensitive assays 
Beckman Coulter Access hs-
cTnI 
8.6 10.0 Guideline >95% 
Roche Elecsys hs-cTnT 13 8.0 Guideline >95% 
Nanosphere hs-cTnI 2.8 9.5 Guideline 75-95% 
Singulex hs-cTnI 10.1 9.0 Guideline >95% 
Table 6. Classification of the current and the high-sensitive cTn assays according criteria of 
Apple 2009.(source) Troponinas ultrasensibles en el dolor torácico y los síndromes 
coronarios agudos. ¿un paso hacia delante? A.S. Jaffé y J.Ordoñez-Llanos. Rev Esp Cardiol, 
2010; 63(7)763-68  
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From these results it is important to point out that the most sensitive methods (research 
high-sensitivity assays) that is, with concentration values under 99th percentile and with 
better imprecisions in such percentile, are the ones which show higher proportion of healthy 
subjects (between 75-95% or >95%) which exceed the value of normality established for the 
method  
4. Repercussion of high sensitivity troponin methods in the management of 
patients with ACS – Proposal of interpretation in clinical practice 
The appearance of this new generation of high sensitivity troponin methods is going to 
modify the classical diagnostic interpretation of precordial pain we have been making 
until now as their goal is to be able to measure much smaller protein concentrations than 
the ones conventional methods are able to measure now. So it will be necessary to learn 
again and become familiar with the management of the marker. These new myocardial 
necrosis biomarkers going to appear in the blood stream hours earlier than if the marker 
is measured using conventional methods. These ones can only detect troponin 6-9 hours 
after clinical symptoms whereas using high sensitivity troponin the necrosis can be 
diagnosed earlier, as it starts being detected in blood three hours after pain. In a similar 
way the exclusion of acute myocardial infarction will also be earlier and considering the 
negligible amount of troponin which can be detected it will also increase the prediction of 
adverse clinical events. There are studies which confirm this fact. As the sensitivity of the 
methods has increased, it has been found a remarkable increase of the diagnostic 
sensitivity in the early detection of AMI using all, methods of high sensitivity troponinT 
and conventional Tn T methods (Giannitsis E,2010, Giannitsis E,2010 b) or troponin I 
(Kavasak PA 2009. Wilson 2009). 
These characteristics which theoretically just show benefits can cause diagnostic confusion 
of an acute coronary syndrome because ultrasensitive troponin elevations are not only 
due to an acute process as they are also found in sub-acute processes and other cardiac 
diseases. High sensitivity troponin methods detect a minimum injury of the non-ischemic 
cardiomiocites, due to cardiac disorders (myocardial injuries such as myocarditis, 
pericarditis among others or the increase of the cardiac size as in cardiac insufficiency, left 
ventricular hypertrophia among others) or to other sort of diseases as for example 
pulmonary edema , sepsis or ictus can cause the release of hsTn into the systemic 
circulation. That is why not only the ischemic injury but also a wide range of other 
alterations can be associated with elevated high sensitivity troponin values. Besides, most 
of these elevations predict an adverse evolution in these patients, being , in this case, the 
clinic criterias the only way to reach a diagnosis. This causes confusion in the 
interpretation of troponin, which has traditionally been associated with the acute 
coronary syndrome being its elevation essential when the patient has acute thoracic pain, 
having or not elevation of the ST segment in electrocardiogram. Using conventional 
methods the finding of troponin values over the reference interval, in processes which do 
not fit with an acute coronary syndrome, induced us to look into the cause, which 
habitually was not explained. The appearance of high sensitivity methods make us change 
our criteria as although the reason for the output into the bloodstream of small amounts 
of the protein, which were not detected by conventional methods, is not known exactly, in 
processes which do not fit with acute ischemia its find represents a very useful data for 
the prognosis of the patient. 
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The appearance of this new generation of methods to assess troponin induces us to 
continue with the research in the management of these biomarkers, whose future is 
promising, in order to optimize and learn its management, and until new Guidelines in 
Clinical Practice appear and reach a consensus on the best way to use and interpret the 
results, we must be cautious in the application of high sensitivity troponin in clinical 
practice methods. 
That is why the best thing to do (table 7) before implementing a method in clinical practice 
is to assess comprehensively and establish the reference values in better defined 
populations, using more strict inclusion criteria, setting up patterns of evolution changes to 
differentiate an ischemic patient from a patient with troponin elevations due to stable 
disease or underlying to new pathologic entities different from acute coronary syndrome. 
The knowledge this data for each of the methods assessing ultrasensitive troponin is an 
essential tool for the correct use and clinical interpretation of the results. Not to have such 
data well defined and established makes the diagnostic interpretation difficult and can 
cause confusion  
 
1. Establishing reference values (99 th percentil discriminator at CV <10%) 
2. Establishing the increase value of high sensitivity troponin discriminator of Acute 
Coronary Syndrome (∆ Tn discriminator). 
Table 7. Mandatory requirements for the use of a high sensitivity troponin method in 
clinical practice 
4.1 Establishing reference values of the method 
As it can be seen in table 7 when there is an increase in the analytical sensitivity of the 
troponin tests, there are more people with troponin concentration over the 99th percentile. 
So, individuals with cardiovascular risk as hypertension, dislipemia, diabetes, renal 
insufficiency, cardiac insufficiency among others. This fact can make the clinical 
interpretation of the test difficult. That is why when evaluating a high sensitivity troponin 
method we must be especially cautious when establishing the reference values (table 8). 
The selection of the individuals to be included as reference population must be much 
more selective, considering much more strict inclusion criteria. The most important 
exclusion criteria to bear in mind are: pregnancy, current cold or infection, chronic 
inflammatory disease, patients treated for cardiac disease or lipid management, diabetes, 
family history of cardiovascular disease, smoking, high blood pressure or treated for high 
blood pressure, increased C-reactive protein, o interleukin-6 among others. The number of 
subjects to study must be at least 120 and 99th percentile will be applied. The imprecision 
of the method in the 99th percentil chosen must be lower or equal to a coefficient of 
variation of 10% (NACB 2007). We must bear in mind that the value of the 99th percentile 
chosen must be higher than the value measured by the method with an imprecision lower 
than 10% (99th percentil discriminator). We could expect that if we carried out again 
reference values in the methods mentioned in tables 5 and 6, with more restrictive 
inclusion criteria applied , especially in the ones called (research high-sensitivity assays), 
the percentage of detectable troponin in normal subjects, exempt from cardiovascular 
pathology, would decrease. 
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Number of patients  Mínimum de 120 subjects 
Exclusion criteria  
- pregnancy  
- infection  
- chronic inflammatory disease 
- subjets treated for cardiac disease or lipid management  
- diabetes  
- subjects with family history of cardiovascular disease  
- smoking  
- high blood pressure  
- increased C-reactive protein or interleukin-6 
statistic 99th percentile 
Precision  CV< 10% in 99th percentile 
Table 8. Requirements to establish reference values of high sensitivity troponin methods 
4.2 Establish the value of increase of high sensitivity troponin discriminator of acute 
coronary syndrome 
As a result of all the above mentioned it is easy to understand the difficulty in interpreting a 
value of basal high sensitivity troponin in patients who go to the emergency room with 
precordial pain and without conclusive alterations in the electrocardiogram. From the 
biochemical point of view, the only way to help to distinguish if a high sensitivity troponin 
elevation is due to an acute ischemia process or if the origin is a sub-acute cardiac disease or 
chronic, as it happens with congestive cardiac insufficiency or cardiomyiopaties among 
others, is to perform serial troponins, as the Guidelines for Clinical Practice in 2007 
recommended (Thygesen 2007, NACB 2007). Nevertheless, given the early of the appearance 
of high sensitivity troponin (3 hours after pain) as well as its high sensitivity in detection, 
the basal determination and the determination 6-9 after pain would not be the protocol to 
choose. With these new generation of troponins, the advisable to distinguish if we are facing 
an acute necrosis process or an underlying ischemia of a chronic process, is to establish a 
value of the increase of troponin discriminator of acute coronary syndrome (∆ Tn 
discriminator). To obtain this data the increase in the variation of troponin should be 
assessed for a 3-hour interval, in a group of patients who suffer from an acute coronary 
syndrome and in another group patients who suffer a chronic process. In the acute ischemia 
there will be a significant increase of basal troponin compared with the one carried out 
between 3 and 6 hours later. In chronic processes the increase in troponin between 3 and 6 
hours compared with basal troponin will be much lower. Once the Tn discriminator for a 
determined method is obtained, in clinical practice the scheme in figure I could be applied, 
which will help us confirm an acute myocardial infarction, at an earlier stage than with 
traditional methods, or to look for other causes of the increase in troponin. 
The correct establishment of the increase evolution of high sensitivity troponin for an acute 
coronary syndrome, together with the strict study of normality values will clarify the 
advantages of this new generation of methods for the early diagnosis of acute coronary 
syndrome, as well as it will significantly benefit in the stratification of the risk, not only in 
patients with acute coronary syndrome but also patients who suffer from other myocardial 
injuries or increase of cardiac size among other causes. 
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Fig. 9. Clinical significance of hsTn using troponin increase ACS discriminator. Proposal for 
the use of high sensitivity troponin in clinical practice. 
5. High sensitivity troponin in patients with heart failure 
Heart failure (HF) is a growing public health problem with high morbidity and mortality 
(Rosamond W 2008) . Natriuretic peptides are the election markers for diagnosis and risk 
stratification of patients with Heart failure ( Braunwald E 2008) . Cardiac troponin are detected 
in an important proportion of patients suffering from acute or chronic HF. The mechanism of 
cardiac damage and appearance in Tn plasma, acute or chronic HF is not exactly known. The 
levels of troponin in plasma are associated with the increase of the risk of morbility and 
mortality either in acute or chronic HF giving prognostic information (Parentini 2008). Cardiac 
troponin is detected in a significant portion of patients with acute and chronic Heart Failure. 
However, the incidence of detection depends on the sensitivity of the assay used. Latini et al ( 
Latini 2007) ,. measured Plasma troponin T in 4053 patients with chronic HF enrolled in the 
Valsartan Heart Failure Trial (Val-HeFT). Troponin T was detectable in 10.4% of the 
population with the conventional cTnT assay (detection limit < or = 0.01 ng/mL) compared 
with 92.0% with the new hsTnT assay (< or = 0.001 ng/mL). Detectable cTnT predicts adverse 
outcomes in chronic HF. (High sensitivity Troponin T (hsTnT) is a novel biomarker that 
provides prognostic information in several clinical settings as heart failure. 
6. Conclusions 
In view of all the above mentioned we can conclude that the biochemical diagnosis of ACS 
continues being a current affair and continues envolving. The process of troponin has not 
finished yet. The appearance of high sensitivity methods seems to be promising. They help 
to diagnose ACS much earlier and obtain higher stratification of the risk than convencional 
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methods. Besides, it will let us know about the prognostic evolution of other pathologies 
such as chronic cardiac insufficiency as well as cardiovascular events in stable coronary 
disease. Nevertheless, to achieve the efficiency that the test deserves we have to learn, again 
to use and interprete the results of ultra-sensitive troponin. It is necessary to consolidate and 
establish firmly the dynamic changes of troponin concentrations to interprete the results 
accurately.  
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